In the current issue of the Journal of Human Hypertension, Mahmud and Feely 1 report on the use of pulse wave analysis (PWA) to assess the effect of the angiotensin II receptor antagonist, valsartan, on arterial stiffness in patients with resistant hypertension. This timely report emphasises the importance of arterial stiffness as a predictor of cardiovascular risk, and the changing perception of the various components of blood pressure over the last 100 years.
Arterial stiffness and cardiovascular risk
The importance of arterial blood pressure as a determinant of cardiovascular risk has been clearly demonstrated by a number of observational and intervention studies conducted since the introduction of the mercury sphygmomanometer at the turn of the last century. However, the component of blood pressure that best predicts cardiovascular risk has been a matter of considerable recent debate.
2 By convention, diastolic pressure was initially considered to be the best predictor of risk, and a high systolic pressure was believed to reflect a strong left ventricle. Despite data in the 1970s and 80s from the Framingham Cohort, 3 demonstrating that systolic pressure was probably more important than diastolic values in defining risk, most physicians remained heavily biased towards diastolic pressure for both risk assessment and treatment. However, overwhelming evidence from epidemiological observations now indicates that, at least in the over 50s, pulse pressure is a more important determinant of cardiovascular risk than mean arterial pressure in normotensive, 4 hypertensive 5 and post-myocardial infarction populations. 6 Recent re-analysis of several blood pressure-lowering studies confirms these findings. 7, 8 Mean arterial pressure, which is most closely related to diastolic pressure, is the product of peripheral vascular resistance and cardiac output. Pulse pressure, however, is mainly determined by large artery compliance and the pattern of left ventricular ejection. Therefore, in middle-aged and older subjects, the available evidence suggests that arterial stiffness is a more important predictor of cardiovascular risk than peripheral vascular resistance. Direct assessment of aortic stiffness using measurement of the pulse wave velocity (PWV) in patients with end-stage renal failure, 9 and hypertension 10 confirms this view.
Pulse wave analysis
Arterial stiffness can be measured in a number of ways. 11 Ultrasound and MRI can be used to assess local distensibility and/or compliance, and a variety of methods exist for assessing PWV, which provides accurate information concerning the distensibility of the arterial segment under investigation. 12 However, such methods do not provide information about systemic arterial compliance and in particular the interaction between the vascular tree and the left ventricle. Pulse wave analysis, offers a non-invasive method for assessment, of systemic arterial stiffness, and also estimation of central arterial pressure. 13 Intermittent left ventricular ejection creates pressure waves that are reflected back, towards the heart from sites of impedance mis-match in the periphery.
14 Therefore, the pressure waveform at any point in the vascular tree is a composite of a forward-going and reflected wave. Normally, the reflected wave returns to the aorta in diastole and boosts coronary artery filling. However, as arteries stiffen, the amplitude and speed of the reflected wave both increase, so that a larger reflected wave returns to the aorta sooner, which changes the shape of the waveform augmenting central systolic pressure.
14 Therefore, the shape of the arterial pressure wave provides useful information concerning systemic arterial stiffness. Mahomed and others recognised this over 100 years ago, 15 and since then a variety of devices have been employed to record and analyse the pressure waveform. 16, 17 However, until recently, PWA was confined to the peripheral waveform. O'Rourke and colleagues have further developed the technique of PWA, making non-invasive derivation of central pressure waveforms possible. 18 Their technique uses applanation tonometry to record accurately pressure waves from the radial artery, 19 and a validated generalised transfer factor [20] [21] [22] [23] [24] is then used to generate the corresponding central arterial waveform. From this, augmentation index (AIx) -a measure of systemic arterial stiffness, the timing of the reflected wave -which provides an estimate of the aortic PWV, 25 and central pressure can be determined noninvasively and reproducibly. 26 Due to differences in vessel compliance and wave reflection, the shape of the arterial waveform, 27, 28 and systolic blood pressure in particular, varies throughout the arterial tree. 29 Peripheral pulse pressure is higher than brachial artery pressure in most individuals -ie, there is amplification moving away from the aorta. 29 However, with age, central pulse pressure rises and the amplification ratio falls, 14 and similar changes might be expected with other conditions, that induce premature vascular stiffening such as hypertension, diabetes mellitus and cigarette smoking. Therefore, simply measuring peripheral pulse pressure will not provide a reliable estimate of central haemodynamics. This is important, because central systolic pressure, not brachial artery pressure, defines left ventricular workload and, therefore, left ventricular massan important and independent predictor of cardiovascular mortality. 30 Moreover, carotid pulse pressure correlates more closely with carotid intimamedia thickness than brachial pulse pressure. 31 However, whether measurement of central pulse pressure will improve risk stratification remains to be proven, although the recent inclusion of PWA, as a sub study, in large randomised intervention trials such as the ASCOT, SEARCH and FIELD studies will hopefully address this issue.
Arterial stiffness and therapeutic intervention
Mahmud and Feely 1 report that addition of the angiotensin receptor antagonist valsartan to standard drug therapy, in patients with resistant hypertension already receiving an angiotensin-converting enzyme (ACE) inhibitor, results in a significant reduction in peripheral blood pressure. They did not observe any serious adverse events with this combination, although theirs was a small study and data from larger studies are required to adequately address this important issue. Interestingly, therapy with valsartan also resulted in a significant reduction in AIx, a measure of systemic arterial stiffness, and an increase in the amplification ratio of peripheral to central pulse pressure, again indicating reduced large artery stiffness.
Although the observed changes in stiffness were highly significant, they must be interpreted with caution, because while both structural and functional components within the vessel wall define large artery stiffness, it is also dependent upon distending pressure, ie, mean arterial pressure.
14 Therefore, some of the beneficial effects observed with valsartan may simply be due to the passive effect of lowering mean arterial pressure. In order to distinguish between passive effects and those due to direct drug actions on arterial structure and function it becomes important to include positive control agents in such studies that will reduce mean arterial pressure to a similar degree as the study drug. Previous studies have, however, demonstrated differences between antihypertensive agents in their effect on large arterial stiffness and wave reflection. [32] [33] [34] Indeed, ACE inhibitors decrease wave reflection and large artery stiffness, 32, 35 whereas at least acutely, ␤-adrenoceptor antagonists have been shown to increase wave reflection. 36 Such observations have important implications for the management of patients with isolated systolic hypertension (ISH), which is primarily a disease of increased arterial stiffness. 37 Isolated systolic hypertension currently affects around 50% of the over 60s, and this number is set to rise substantially with increasing life expectancy over the next 20 years. Most of the drugs currently used in patients with ISH were developed to treat essential hypertension, a disease of increased peripheral vascular resistance, and thus were targeted at the resistance vessels. Improved treatment of ISH requires new drugs which selectively target the large arteries and improve arterial compliance both directly, by functional and structural modifications, and indirectly, by reducing mean pressure. To some extent nitrates may be useful in this respect, although nitrate tolerance and ignorance of the different mechanisms underlying essential hypertension and ISH have prevented a proper randomised controlled trial investigating the effectiveness of sustained-action oral nitrates.
The vascular endothelium produces a number of vasoactive mediators such as nitric oxide and endothelin that regulate smooth muscle tone and, are thus likely to contribute to the functional control of large artery stiffness. Endothelial dysfunction, which is present in most patients with established cardiovascular risk factors, may explain why conditions such as diabetes and hypercholesterolaemia also associated with increased large artery stiffness, at an early stage, before the development of manifest atheroma. 38 Therefore, drugs that improve endothelial function, such as ACE inhibitors, may also be useful in these conditions. As yet, little is known about the effects of angiotensin II receptor antagonism on endothelial function, although recently the angiotensin II receptor antagonist losartan has been shown to prevent endothelial dysfunction induced by triglyceride-rich lipoproteins in healthy volunteers. 39 Mahmud and Feely suggest that valsartan may exert its beneficial effect on arterial stiffness and wave reflection by improving endothelial function. This view is supported by our own recent data demonstrating an inverse correlation between endothelial dysfunction and AIx in a group of growth hormone deficient subjects. 40 However, further work investigating the link between endothelial function and arterial stiffness is required in this emerging field.
In summary, arterial stiffness is a key determinant of cardiovascular risk in older individuals, and drugs that target large artery stiffness will be increasingly important in the treatment of ISH. A number of methods exist for assessing stiffness. PWA is one such technique that has a number of advantages: it is simple, non-invasive and reproducible, and also provides an estimation of central blood pressure.
